

# Metabolites from *Aspergillus versicolor*, an endolichenic fungus from the lichen *Lobaria retigera*

Yanli Dou<sup>1</sup>, Xiaoling Wang<sup>2</sup>, Daifeng Jiang<sup>3</sup>, Haiying Wang<sup>3</sup>, Yang Jiao<sup>1</sup>, Hongxiang Lou<sup>1</sup>, Xiaoning Wang<sup>1,\*</sup>

<sup>1</sup> Department of Natural Product Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong, China;

<sup>2</sup> The Second Hospital of Shandong University, Ji'nan, Shandong, China;

<sup>3</sup> College of Life Sciences, Shandong Normal University, Ji'nan, Shandong, China.

**Summary** Three new anthraquinone derivatives (**1-3**) and one new artifact (**4**) were isolated, along with six known anthraquinone derivatives (**5-10**) and three xanthenes (**11-13**), from a culture of an endolichenic fungus, *Aspergillus versicolor*, that was isolated from the lichen *Lobaria retigera*. The structures of these substances were determined on the basis of 1D and 2D (COSY, HMQC, and HMBC) NMR and MS analyses. The substances **1-4** were also tested for their cytotoxic activity.

**Keywords:** Endolichenic fungus, *Aspergillus versicolor*, *Lobaria retigera*, anthraquinone

## 1. Introduction

Lichens are composite organisms of a fungus (the mycobiont) and an algal partner (the photobiont or phycobiont) growing together in a symbiotic relationship. Endolichenic fungi, an emerging group of endosymbiotic microorganisms, consist of fungal strains that live within asymptomatic lichen thalli, much in the same way as endophytic fungi live within healthy plant tissues (*1*). In contrast to endophytic fungi that have been studied chemically a number of times (*2-4*), only a limited number of endolichenic fungi have thus far been investigated for their secondary metabolites (*5,6*), but studies have shown that endolichenic fungi are also rich sources of structurally diverse and biologically active small-molecule metabolites. In the course of the current authors' ongoing efforts to discover bioactive compounds from endophytic and endolichenic microorganisms, four new anthraquinone derivatives (**1-4**) (Figure 1) were obtained, along with six known anthraquinones (**5-10**) and three xanthenes (**11-13**) (Supplemental data, <http://www.ddtjournal.com/docindex.php?year=2014&kanno=2>), from a culture of *Aspergillus versicolor*, an endolichenic

strain of the lichen *Lobaria retigera*. The structures of these substances were elucidated using spectroscopic methods, including 1D and 2D nuclear magnetic resonance (NMR) and high-resolution electrospray ionization mass spectrometry (HRESIMS). Substances **1-4** were tested for their cytotoxic activity, with **1** and **2** displaying weak inhibitory activity towards the PC-3 and H460 human cancer cell lines. Reported here are the isolation of these compounds, elucidation of their structures, and determination of their bioactivity.

## 2. Materials and Methods

### 2.1. General experimental procedures

Optical rotations were measured on a GYROMAT-HP




Figure 1. Structures of compounds **1-4**

\*Address correspondence to:

Dr. Xiaoning Wang, Department of Natural Product Chemistry, Shandong University, 44 West Wenhua Road, Ji'nan 250012, Shandong, China.  
E-mail: wangxn@sdu.edu.cn

polarimeter (Shimadzu Corporation, Kyoto, Japan). Infrared spectra (IR) were recorded on a Nicolet iN 10 Micro FTIR spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) in transmission mode. Ultraviolet (UV) spectra were obtained with a Shimadzu UV-2550 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). NMR spectra were recorded on a Bruker Avance DRX-600 spectrometer (Bruker BioSpin Group, Billerica, MA, USA) operating at 600 ( $^1\text{H}$ ) and 150 ( $^{13}\text{C}$ ) MHz with tetramethylsilane (TMS) as an internal standard. HRESIMS was performed on an LTQ Orbitrap XL (Thermo Fisher Scientific Inc., Waltham, MA, USA). All solvents used were of analytical grade (Laiyang Chemical Reagent Co., Ltd., Shandong, China). High-performance liquid chromatography (HPLC) was performed on an Agilent 1100 G1310A isopump equipped with an Agilent 1100 G1322A degasser, an Agilent 1100 G1314A VWD detector (254 nm), and an Agilent ZORBAX SB-C<sub>18</sub> column (9.4 mm × 250 mm, 5 μm) (Agilent Technologies, Inc., Santa Clara, CA, USA). Silica gel (200-300 mesh; Qingdao Haiyang Chemical Co., Ltd., Qingdao, Shandong, China), C<sub>18</sub> reversed-phase silica gel (YMC ODS-A gel, YMC Co., Ltd., Kyoto, Japan), and Sephadex LH-20 (GE Health, Uppsala, Sweden) were used for column chromatography (CC). Thin-layer chromatography (TLC) was performed with high-performance TLC plates precoated with silica gel GF254 (Qingdao Haiyang Chemical Co., Ltd.). Spots of TLC were visualized within iodine vapor or by spraying with H<sub>2</sub>SO<sub>4</sub>-EtOH (1:9) followed by heating.

## 2.2. Microorganism

The strain of fungus was isolated from the lichen *Lobaria retigera* collected from Mount Laojun, Yunnan Province, China. Nuclear ITS rDNA sequencing revealed that it was *Aspergillus versicolor*. The fungus (accession no. 2011-WX-35b) was deposited in the Key Laboratory of Chemical Biology (Ministry of Education).

## 2.3. Fermentation, extraction, and isolation

The fungal strain was grown on slants of potato dextrose agar (PDA) at 25°C for 15 days. The fungus was then placed in five Erlenmeyer flasks (300 mL) that each contained 120 mL of potato dextrose broth (PDB). These flasks were incubated at 25°C on a rotary shaker (120 rpm) for seven days to obtain the seed culture. The seed broth was added to 40 flasks (500 mL) that each contained an autoclaved culture medium of rice (80 g) and water (120 mL). Afterwards, the flasks were left to stand at room temperature for 40 days until the solid medium had almost disappeared. At harvest, the culture medium containing the mycelium was cut into small pieces, extracted with EtOAc for two days at

room temperature, and then filtered. The solvent was evaporated under reduced pressure at 38°C to yield a crude extract (36.0 g) that was separated using CC with silica gel eluted with a gradient of petroleum ether (PE) and acetone from 100:0 to 0:100 (v/v) to yield eleven fractions (Fr. A-Fr. K). Fr. D (771.7 mg) was separated using CC with silica gel (PE/acetone, 80:1 to 2:1) to yield six subfractions (Fr. D1-Fr. D6). Compound **11** (101.5 mg) was obtained from Fr. D2 after recrystallization in CH<sub>2</sub>Cl<sub>2</sub>. Fr. D4 (230.0 mg) was loaded onto a Sephadex LH-20 column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 1:1) to yield **4** (10.0 mg) and **5** (28.3 mg). Fraction E (80.0 mg) was separated using CC with a Sephadex LH-20 column (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 1:1) to yield the primary portion (16.2 mg), which was further purified using HPLC (MeOH-H<sub>2</sub>O, 90:10, 1.5 mL/min) to yield **9** (3.0 mg,  $t_{\text{R}} = 10.9$  min). Fraction G (2.0 g) was separated using CC with silica gel eluted with a gradient of CH<sub>2</sub>Cl<sub>2</sub>-MeOH (60:1 to pure MeOH) to yield seven subfractions (Fr. G1-Fr. G7). After recrystallization in CH<sub>2</sub>Cl<sub>2</sub>, compounds **6** (8.2 mg) and **7** (10.3 mg) were obtained from Fr. G3 (26.0 mg) and Fr. G2 (29.4 mg), respectively. Fr. G6 (638.7 mg) was subjected to CC with C18 reversed-phase silica gel eluted with a gradient of MeOH-H<sub>2</sub>O (50:50 to 100% MeOH) to yield the primary portion, which was further separated using HPLC (MeOH-H<sub>2</sub>O, 67:33, 1.5 mL/min) to yield **13** (2.1 mg,  $t_{\text{R}} = 34.2$  min) and **12** (4.7 mg,  $t_{\text{R}} = 23.4$  min). Fraction H (3.6 g) was subjected to CC with silica gel eluted with a gradient of CH<sub>2</sub>Cl<sub>2</sub>-MeOH (80:1 to 5:1) to yield eight subfractions (Fr. H1-Fr. H8). Fr. H4 (430.9 mg) was first separated on silica gel eluted with a gradient of PE-EtOAc (40:1 to 10:1) to yield the primary portion and then separated on C18 reversed-phase silica gel eluted with a gradient of MeOH-H<sub>2</sub>O (50:50 to pure MeOH) to yield six subfractions (Fr. H4-1-Fr. H4-6). Fr. H4-4 (53.1 mg) was purified using HPLC (CH<sub>3</sub>CN-H<sub>2</sub>O, 50:50, 1.5 mL/min) to yield **1** (3.2 mg,  $t_{\text{R}} = 19.6$  min) and **2** (2.0 mg,  $t_{\text{R}} = 21.4$  min). Fr. H4-5 (38.4 mg) yielded **10** (5.1 mg,  $t_{\text{R}} = 34.2$  min) after HPLC (MeOH-H<sub>2</sub>O, 75:25, 1.5 mL/min) purification. Fr. H5 (637.4 mg) was separated on a silica gel column eluted with a gradient of PE-EtOAc (20:1 to 1:1) to yield five subfractions (Fr. H5-1-Fr. H5-5). Fr. H5-2 (44.9 mg) was purified using HPLC (CH<sub>3</sub>CN-H<sub>2</sub>O, 70:30, 1.5 mL/min) to yield **8** (20.0 mg,  $t_{\text{R}} = 28.2$  min), while Fr. H5-4 (25.0 mg) yielded **3** (4.8 mg,  $t_{\text{R}} = 24.2$  min) after HPLC (CH<sub>3</sub>CN-H<sub>2</sub>O, 64:36, 1.5 mL/min) purification.

8-*O*-methylversicolorin B (**1**): Orange solid.  $[\alpha]_{\text{D}}^{20} = -75.76$  ( $c$  0.132, MeOH). UV (MeOH)  $\lambda_{\text{max}}$  (log $\epsilon$ ) nm: 197 (1.65), 223 (2.08), 287 (1.53), 310 (0.96). IR (KBr)  $\nu_{\text{max}}$  cm<sup>-1</sup>: 3,494, 2,946, 2,851, 1,620, 1,598, 1,242, 949. HRESIMS (negative mode)  $m/z$  353.0635 [ $M-H$ ]<sup>-</sup> (calcd. for C<sub>19</sub>H<sub>13</sub>O<sub>7</sub>, 353.0661). For  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data, see Tables 1 and 2.

8-*O*-methylversicolorin A (**2**): Orange solid.  $[\alpha]_{\text{D}}^{20} =$

**Table 1.** <sup>1</sup>H-NMR data for compounds 1-4 (at 600 MHz,  $\delta$  in ppm,  $J$  in Hz)

Position	1 <sup>a</sup>	2 <sup>a</sup>	3 <sup>a</sup>	4 <sup>b</sup>
4	6.99 (1H, <i>s</i> )	7.14 (1H, <i>s</i> )	7.26 (1H, <i>s</i> )	7.08 (1H, <i>s</i> )
5	7.26 (1H, <i>s</i> )	7.33 (1H, <i>s</i> )	7.31 (1H, <i>s</i> )	7.45 (1H, <i>s</i> )
7	6.70 (1H, <i>s</i> )	6.92 (1H, <i>s</i> )	6.91 (1H, <i>s</i> )	6.78 (1H, <i>s</i> )
1-OH	14.44 (1H, <i>brs</i> )	13.89 (1H, <i>s</i> )	14.58 (1H, <i>s</i> )	13.76 (1H, <i>s</i> )
3-OH				9.72 (1H, <i>s</i> )
6-OCH <sub>3</sub>				4.00 (3H, <i>s</i> )
8-OCH <sub>3</sub>	3.89 (3H, <i>s</i> )	3.97 (3H, <i>s</i> )	3.97 (3H, <i>s</i> )	4.02 (3H, <i>s</i> )
1'	6.45 (1H, <i>d</i> , $J = 4.2$ )	6.9 (1H, <i>d</i> , $J = 4.2$ )	6.74 (1H, <i>d</i> , $J = 16.2$ )	5.03 (1H, <i>m</i> )
2'	4.15 (1H, <i>t</i> , $J = 6.6$ )	4.80 (1H, <i>m</i> )	7.02 (1H, <i>dt</i> , $J = 16.2, 7.2$ )	1.75 (2H, <i>m</i> )
3'	2.23 (1H, <i>m</i> ) ( $\beta$ -H); 2.28 (1H, <i>m</i> ) ( $\alpha$ -H)	5.45 (1H, <i>m</i> )	2.28 (1H, <i>q</i> , $J = 7.2$ )	1.70 (2H, <i>m</i> )
4'	3.58 (1H, <i>m</i> ) ( $\beta$ -H); 4.09 (1H, <i>t</i> , $J = 7.8$ ) ( $\alpha$ -H)	6.65 (1H, <i>s</i> )	1.49 (2H, <i>m</i> )	1.30 (2H, <i>m</i> )
5'			1.40 (2H, <i>m</i> )	1.25 (2H, <i>m</i> )
6'			0.94 (3H, <i>t</i> , $J = 7.2$ )	0.87 (3H, <i>m</i> )
1''				3.60 (2H, <i>m</i> )
2''				1.26 (3H, <i>m</i> )

<sup>a</sup> Measured in acetone-*d*<sub>6</sub>; <sup>b</sup> Measured in CDCl<sub>3</sub>

**Table 2.** <sup>13</sup>C-NMR data for compounds 1-4 (at 150 MHz,  $\delta$  in ppm)

Position	1 <sup>a</sup>	2 <sup>a</sup>	3 <sup>a</sup>	4 <sup>b</sup>
1	165.2 (C)	n.o. <sup>c</sup>	161.1 (C)	162.0 (C)
2	120.8 (C)	120.9 (C)	119.2 (C)	119.7 (C)
3	160.7 (C)	164.1 (C)	164.0 (C)	162.4 (C)
4	99.97 (CH)	100.2 (CH)	107.2 (CH)	108.6 (CH)
4a	136.0 (C)	134.7 (C)	132.0 (C)	132.9 (C)
5	110.5 (CH)	107.0 (CH)	107.6 (CH)	103.8 (CH)
6	169.7 (C)	164.8 (C)	163.5 (C)	164.9 (C)
7	106.2 (CH)	104.9 (CH)	105.7 (CH)	104.9 (CH)
8	165.3 (C)	163.2 (C)	164.8 (C)	162.8 (C)
8a	112.0 (C)	n.o. <sup>c</sup>	114.6 (C)	137.6 (C)
9	186.8 (C)	186.6 (C)	187.6 (C)	186.8 (C)
9a	113.7 (C)	n.o. <sup>c</sup>	111.3 (C)	110.2 (C)
10	183.8 (C)	181.9 (C)	182.8 (C)	182.6 (C)
10a	138.0 (C)	137.3 (C)	132.0 (C)	115.4 (C)
6-OCH <sub>3</sub>				56.0 (CH <sub>3</sub> )
8-OCH <sub>3</sub>	56.4 (CH <sub>3</sub> )	55.9 (CH <sub>3</sub> )	56.8 (CH <sub>3</sub> )	56.7 (CH <sub>3</sub> )
1'	114.0 (CH)	113.2 (CH)	120.4 (CH)	77.6 (CH)
2'	45.2 (CH)	48.9 (CH)	139.1 (CH)	34.8 (CH <sub>2</sub> )
3'	31.5 (CH <sub>2</sub> )	101.7 (CH)	35.4 (CH <sub>2</sub> )	31.6 (CH <sub>2</sub> )
4'	68.1 (CH <sub>2</sub> )	145.5 (CH)	32.6 (CH <sub>2</sub> )	25.1 (CH <sub>2</sub> )
5'			23.1 (CH <sub>2</sub> )	22.6 (CH <sub>2</sub> )
6'			14.0 (CH <sub>3</sub> )	14.1 (CH <sub>3</sub> )
1''				66.3 (CH <sub>2</sub> )
2''				15.0 (CH <sub>3</sub> )

<sup>a</sup> Recorded in acetone-*d*<sub>6</sub>; <sup>b</sup> Measured in CDCl<sub>3</sub>; <sup>c</sup> These quaternary carbons were not observed.

– 95.24 (*c* 0.063, MeOH). UV (MeOH)  $\lambda_{\max}$  (log $\epsilon$ ) nm: 197 (1.16), 223 (1.06), 285 (0.81). IR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3,366, 2,921, 2,851, 1,738, 1,630, 1,598, 1,347, 1,294, 1,223, 973. HRESIMS (negative mode)  $m/z$  351.0503 [M-H]<sup>-</sup> (calcd. for C<sub>19</sub>H<sub>11</sub>O<sub>7</sub>, 351.0505). For <sup>1</sup>H- and <sup>13</sup>C-NMR data, see Tables 1 and 2.

8-*O*-methylaverythin (**3**): Orange solid. UV (MeOH)  $\lambda_{\max}$  (log $\epsilon$ ) nm: 195 (2.30), 225 (2.45), 295 (2.90). IR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3,529, 3,377, 3,089, 3,027, 2,956, 2,927, 2,856, 1,618, 1,583, 1,336, 1,300, 1,258, 1,061, 978. HRESIMS (negative mode)  $m/z$  367.1177 [M-H]<sup>-</sup> (calcd. for C<sub>21</sub>H<sub>19</sub>O<sub>6</sub>, 367.1182). For <sup>1</sup>H- and <sup>13</sup>C-NMR data, see Tables 1 and 2.

1'-*O*-ethyl-6,8-di-*O*-methylaverantin (**4**): Yellow solid.  $[\alpha]_{\text{D}}^{20} = -11.63$  (*c* 0.086, MeOH). UV (MeOH)  $\lambda_{\max}$  (log $\epsilon$ ) nm: 197 (3.02), 224 (3.79), 286 (3.14). IR (KBr)  $\nu_{\max}$  cm<sup>-1</sup>: 3,219, 2,926, 2,854, 1,736, 1,670, 1,622, 1,595, 1,333, 1,265, 1,162, 1,063. HRESIMS (positive mode)  $m/z$  429.1908 [M+H]<sup>+</sup> (calcd. for C<sub>24</sub>H<sub>29</sub>O<sub>7</sub>, 429.1913). For <sup>1</sup>H- and <sup>13</sup>C-NMR data, see Tables 1 and 2.

#### 2.4. Cytotoxicity assay

A tetrazolium-based colorimetric assay (MTT assay) was used to determine cell viability. PC-3 cells (ATCC CRL-1435 human prostate adenocarcinoma) and NCI-H460 cells (ATCC HTB 177 human lung carcinoma) were used. The cell culture and cytotoxic activity assay followed the same procedures as previously described (7). Doxorubicin was used as a positive control, for which the IC<sub>50</sub> values were 0.2 and 0.3  $\mu$ M against PC-3 and NCI-H460, respectively.

### 3. Results and Discussion

Compound **1** was obtained as an orange powder. HRESIMS revealed a pseudo molecular ion [M-H]<sup>-</sup> peak at  $m/z$  353.0635 (calcd. 353.0661) compatible with the molecular formula C<sub>19</sub>H<sub>14</sub>O<sub>7</sub>, indicating 13 degrees of unsaturation. Evident in the <sup>1</sup>H-NMR spectrum for this compound (Table 1) was the resonance of one hydro-bonded phenolic hydroxyl group at  $\delta_{\text{H}}$  14.44 (*s*), three aromatic protons at  $\delta_{\text{H}}$  7.26 (*s*), 6.99 (*s*), and 6.70 (*s*), an oxygenated methine at  $\delta_{\text{H}}$  6.45 (*d*,  $J = 4.2$  Hz), a methine at  $\delta_{\text{H}}$  4.15 (*t*,  $J = 6.6$  Hz), a pair of oxygen-bearing methylene protons at  $\delta_{\text{H}}$  4.09 (*t*,  $J = 7.8$  Hz) and  $\delta_{\text{H}}$  3.58 (*m*), another methylene at  $\delta_{\text{H}}$  2.28 (*m*) and  $\delta_{\text{H}}$  2.23 (*m*), and one oxygenated methyl group at  $\delta_{\text{H}}$  3.89 (3H, *s*). Evident in the <sup>13</sup>C-NMR spectrum (Table 2) was resonance of two carbonyls ( $\delta_{\text{C}}$  186.8 and 183.8), three aromatic methines, and nine aromatic quaternary

carbons (including four oxygenated) with chemical shifts attributable to a highly substituted anthraquinone scaffold (**8**). In addition, two methylenes (including one oxygenated), two methines, and one oxygenated methyl groups were observed. These data indicated that **1** was similar to versicolorin B (**9**), except that a methoxy group was present at C-6 in **1** instead of the 6-OH group in versicolorin B. The relative configuration of **1** was determined by analysis of NOESY correlations. Therefore, compound **1** was determined to be 8-*O*-methylversicolorin B.

Compound **2** was also an orange amorphous solid. HRESIMS revealed an  $[M-H]^-$  ion peak at  $m/z$  351.0503 (calcd. 351.0505) corresponding to the molecular formula  $C_{19}H_{12}O_7$ . The  $^1H$ - and  $^{13}C$ -NMR data (Tables 1 and 2) for **2** closely resembled those for **1**, except for the presence of an additional double bond between C-3' ( $\delta_C$  101.7) and C-4' ( $\delta_C$  145.5) in **2**. This was verified by the HMBC correlations of H-3' ( $\delta_H$  5.45)/C-1' and H-1'/C-2', C-3', and C-4' along with the  $^1H$ - $^1H$  COSY correlations of H-2'/H-3' and H-3'/H-4'. Therefore, compound **2** was identified as 8-*O*-methylversicolorin A.

Compound **3** was also an orange solid. A molecular formula of  $C_{21}H_{20}O_6$  was assigned to **3** based on the quasimolecular ion  $[M-H]^-$  peak at  $m/z$  367.1177 (calcd. 367.1182) according to HRESIMS. The  $^1H$ - and  $^{13}C$ -NMR spectra for **3** (Tables 1 and 2) were similar to those previously reported for averythrin (**8**) (**8**). The only difference was replacement of 8-OH by a methoxy group ( $\delta_H$  3.97, 3H, s). This was confirmed by HMBC correlations from 8-OMe to C-7 ( $\delta_C$  105.7) and C-8 ( $\delta_C$  164.8). Therefore, compound **3** was determined to be 8-*O*-methylaverythrin.

Compound **4** was obtained as a yellow solid. It was assigned a molecular formula of  $C_{24}H_{28}O_7$  based on the  $[M+H]^+$  ion peak at  $m/z$  429.1908 (calcd. 429.1913) according to HRESIMS. The NMR data for **4** (Table 1) were similar to those for **5** (**10**), except that the 1'-methoxy group in **5** was replaced by an ethoxy moiety in **4**. This was verified by the HMBC correlations of H-2" ( $\delta_H$  1.26)/C-1" ( $\delta_C$  66.3) and H-1" ( $\delta_H$  3.60)/C-1'. Hence, compound **4** was determined to be 1'-*O*-ethyl-6,8-di-*O*-methylaverantin. Compound **4** may be an artifact since EtOH was used in the separation process.

The known compounds 6,8,1'-tri-*O*-methylaverantin (**5**) (**10**), aversin (**6**) (**11-13**), 6,8-di-*O*-methylversicolorin A (**7**) (**11,14**), averythrin (**8**) (**8,9,15,16**), 6,8-di-*O*-methylaverufin (**9**) (**10**), 6,8-di-*O*-methylnidurufin (**10**) (**10**), sterigmatocystin (**11**) (**13,17**), 5-methoxysterigmatocystin (**12**) (**13**), and dihydrosterigmatocystin (**13**) (**17**) were identified by comparing their NMR data (see Supplemental Data) to those reported in the literature.

The *in vitro* inhibition of cell proliferation of two cancer cell lines, PC-3 (human prostate cancer cells)

and H460 (human lung cancer cells), was evaluated using the new compounds **1-4**. Compounds **1** and **2** had weak cytotoxic activity, with  $IC_{50}$  values of 19.5 and 12.6  $\mu$ M against PC-3 cells and 27.2 and 17.3  $\mu$ M against H460 cells. The other compounds had no activity against PC-3 and H460 cells ( $IC_{50} > 50 \mu$ M).

### Acknowledgement

This work was financially supported by the National Natural Science Foundation of China (Grant No. 21272139).

### References

1. Arnold AEM, Higgins J, Sarvate KL, Gugger SD, Way P, Hofstetter A, Kauff V, Lutzoni F. A phylogenetic estimation of trophic transition networks for ascomycetous fungi: Are lichens cradles of symbiotrophic fungal diversification? *Syst Biol.* 2009; 58:283-297.
2. Zhang HW, Song YC, Tan RX. Biology and chemistry of endophytes. *Nat Prod Rep.* 2006; 23:753-771.
3. Verma VC, Kharwar RN, Strobel GA. Chemical and functional diversity of natural products from plant associated endophytic fungi. *Nat Prod Comm.* 2009; 4:1511-1532.
4. Debbab A, Aly AH, Proksch P. Bioactive secondary metabolites from endophytes and associated marine derived fungi. *Fungal Divers.* 2011; 49:1-12.
5. Zhang F, Li L, Niu S, Si Y, Guo L, Jiang X, Che Y. A thiopyranochromenone and other chromone derivatives from an endolichenic fungus, *Preussia Africana*. *J Nat Prod.* 2012; 75:230-237.
6. Wijeratne EK, Bashyal BP, Gunatilaka MK, Arnold AE, Gunatilaka AL. Maximizing chemical diversity of fungal metabolites: Biogenetically related heptaketides of the endolichenic fungus *Corynespora* sp. *J Nat Prod.* 2010; 73:1156-1159.
7. Di X, Wang S, Wang B, Liu Y, Yuan H, Lou H, Wang X. New phenolic compounds from the twigs of *Artocarpus heterophyllus*. *Drug Discov Ther.* 2013; 7:24-28.
8. Huang H, Wang F, Luo M, Chen Y, Song Y, Zhang W, Zhang S, Ju J. Halogenated anthraquinones from the marine-derived fungus *Aspergillus* sp. SCSIO F063. *J Nat Prod.* 2012; 75:1346-1352.
9. Stoessel A, Stothers J. Minor anthraquinonoid metabolites of *Cercospora arachidicola*. *Can J Chem.* 1985; 63:1258-1262.
10. Shao C, Wang C, Wei M, Li S, She Z, Gu Y, Lin Y. Structural and spectral assignments of six anthraquinone derivatives from the mangrove fungus (ZSUH-36). *Magn Reson Chem.* 2008; 46:886-889.
11. Maskey RP, Grun-Wollny I, Laatsch H. Isolation, structure elucidation and biological activity of 8-*O*-methylaverufin and 1,8-*O*-dimethylaverantin as new antifungal agents from *Penicillium chrysogenum*. *J Antibiot.* 2003; 56:459-463.
12. Mori H, Kitamura J, Sugie S, Kawai K, Hamasaki T. Genotoxicity of fungal metabolites related to aflatoxin B1 biosynthesis. *Mutat Res Lett.* 1985; 143:121-125.
13. Shao C, She Z, Guo Z, Peng H, Cai X, Zhou S, Gu Y, Lin Y.  $^1H$  and  $^{13}C$  NMR assignments for two



- anthraquinones and two xanthenes from the mangrove fungus (ZSUH-36). *Magn Reson Chem.* 2007; 45:434-438.
14. Hatsuda Y, Hamasaki T, Ishida M, Kiyama Y. 6,8-O-dimethylversicolorin A, a new metabolite from *Aspergillus versicolor*. *Agric Biol Chem.* 1971; 35:444-446.
  15. Bennett J, Lee L, Shoss S, Boudreaux G. Identification of averantin as an aflatoxin B1 precursor: Placement in the biosynthetic pathway. *Appl Environ Microbiol.* 1980; 39:835-839.
  16. Gorst-Allman CP, Pachler KG, Steyn PS, Wessels PL. Carbon-13 nuclear magnetic resonance assignments of some fungal C20 anthraquinones: Their biosynthesis in relation to that of aflatoxin B1. *J Chem Soc Perkin Trans.* 1977; 1:2181-2188.
  17. YM Lee, Li H, Hong J, Cho HY, Bae KS, Kim MA, Kim DK, Jung JH. Bioactive metabolites from the sponge-derived fungus *Aspergillus versicolor*. *Arch Pharmacol Res.* 2010; 33:231-235.
- (Received January 28, 2014; Revised March 20, 2014; Accepted March 27, 2014)